SUNFLOWER(SZ:300111) Chang Jiang Shang Bao·2025-09-09 04:18Core Viewpoint - The company, Sunflower (300111.SZ), announced a significant asset restructuring plan involving the acquisition of controlling stakes in two companies, which led to a notable increase in its stock price prior to the announcement [1][4]. Group 1: Acquisition Details - Sunflower plans to acquire a controlling stake in Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. through a combination of share issuance and/or cash payment [1][4]. - The transaction is still in the planning stage, and the valuations of the target companies have not been finalized [4]. - The acquisition of Beid Pharmaceutical, if successful, would make it a wholly-owned subsidiary of Sunflower [8][6]. Group 2: Financial Performance - Sunflower's financial performance has been under pressure, with a reported revenue of 144 million yuan in the first half of 2025, a year-on-year decrease of 8.33%, and a net profit of only 1.16 million yuan, down 35.68% [2][11]. - The company has experienced declining revenues and profits since its peak in 2010, with significant fluctuations in net profit over the years [10][11]. Group 3: Market Reaction and Uncertainties - Prior to the announcement, Sunflower's stock price surged by over 14% on September 5, 2025, before closing with an 11.96% increase [2][8]. - There are market concerns regarding the feasibility of the acquisitions, especially given Sunflower's history of unsuccessful cross-industry ventures [3][9].